US and Indian Pharmacopeias Collaborate on Drug Quality
The two pharmacopeias signed a Memorandum of Understanding as recognition of their collaboration for developing international science-based standards.
The US Pharmacopeial Convention (USP) announced on March 17, 2017 that it had signed a Memorandum of Understanding (MOU) with the Indian Pharmacopoeia Commission (IPC) in recognition of the two pharmacopeias’ collaboration in identifying and developing science-based standards. The two organizations have committed to working together to increase awareness of the importance of quality and safety of medications and safeguard the quality of and access to the drug supply chain.
USP and IPC have collaborated on projects in the past, and USP CEO Dr. Ronald T. Piervincenzi stated, in a press release, that he felt the MOU would be “a significant step forward in how two standard setting bodies can work together to improve global health through quality standards … Our collaboration will amplify the global public health impact of both organizations by leveraging our mutual scientific resources to advance international standards.”
Source: USP
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
